We have previously described a number of lipophilic conformationally constrained spiro carbocyclic 2,6-diketopiperazine (2,6-DKP)-1-acetohydroxamic acids as potent antitrypanosomal agents. In this report, we extend the SAR analysis in this class 
| INTRODUCTION
Trypanosomatid protozoan parasites of the genera Trypanosoma and Leishmania are the etiological agents of serious diseases; human African trypanosomiasis (HAT or sleeping sickness), Chagas disease and the leishmaniases (cutaneous, mucocutaneous and visceral). These three parasitic diseases severely affect human health, representing a huge social and economic burden. As recently as the turn of the century, there were estimated to be 0.3 million infections with T. brucei annually, although the numbers have since fallen significantly. 1 In Latin America, 5-8 million people are currently infected with Trypanosoma cruzi, [1] and globally there are an estimated 1 million new infections with different Leishmania species each year. 2 As there are no human vaccines, prevention and treatment of these devastating diseases rely on public health measures and chemotherapy. Unfortunately, the current drugs have many limitations. Pentavalent antimony, the most widely prescribed treatment for visceral leishmaniasis, since its introduction several decades ago, has shortcomings which include serious sideeffects, the requirement for a prolonged course of treatment, and the emergence of drug resistance. [2] Similarly, other visceral leishmaniasis drugs which have emerged over the past 10-15 years, also have drawbacks. With paromomycin, difficulties include administration (injectable, long treatment) and region-dependent efficacy. With miltefosine, the problems are high cost, long treatment and the potential for teratogenicity. With the liposomal amphotericin B, high cost is also an issue, together with the need for hospitalization and potential teratogenicity. [3] For HAT, the first-line treatment for second-stage infections, since its introduction in 1949, has been the arsenicbased drug melarsoprol. However, it kills 5% those treated. [4] In addition, increased drug resistance and high therapeutic failure rates have been reported recently in several foci. [5] Eflornithine, an alternative treatment, now given in combination with nifurtimox, is better tolerated, but difficult to administer. [6] Despite the urgency to develop new drugs for these neglected diseases, research and development have been limited by the lack of commercial interest.
We have previously reported on a series of acetohydroxamic acid analogues ( Figure 1 , compounds 1a-c, 1f, 1g, 2, 6a-c, 6f, 7a, 7b) which have potent antitrypanosome activity. [7] These compounds were derived from conformationally constrained lipophilic spiro carbocyclic 2,6-diketopiperazine (2,6-DKP) scaffolds by introducing an acetohydroxamic acid moiety (CH 2 CONHOH) into their imidic nitrogen atom. The hydroxamic acid unit (CONHOH) is indispensable for trypanocidal activity in this class of compound. [7] Thus, we assumed that these primary hydroxamic acids act by inhibiting a vital parasite metalloenzyme via the metal ion binding action of the hydroxamate group in the catalytic site. It was also found that the potency of this acetohydroxamic acid-based trypanocidal agents was affected by: (a) the structure of the spiro carbocyclic ring and, (b) the presence of alkyl substituents on either the basic nitrogen atom (N-methylation), or at its vicinal position (C-methylation or benzylation) in the spiro carbocyclic 2,6-DKP portion. Notably, attaching a benzyl group to the position adjacent to amine nitrogen (C-benzylation) significantly improved the potency against T. brucei and T. cruzi (Table 1 , compounds 1f, 1g, 2, 6f) relative to the parent compounds (1a, 6a). This finding revealed that the stereoelectronic features and lipophilicity of the substituent at the above position play an important role in the potency of this class of hydroxamates. Subsequently, we have shown that the introduction of a methyl substituent into the nitrogen atom of the hydroxamic unit (CONHOH) results in inactive compounds (Table 1 , 1a, 2 versus 4, 5). [8] The present work is an extension of our ongoing efforts to enrich the structure-activity relationships based on the variation of the alkyl or benzyl substituent at the position adjacent to the amine nitrogen of the 2,6-DKP ring. Thus, we incorporated at this position an isobutyl (compounds 1d, 6d, 7d), a 2-(methylthio)ethyl (compound 1e) or a 4-chlorobenzyl group (compound 3). The trypanocidal properties of the newly synthesized compounds were assessed against cultured bloodstream form T. brucei. In addition, compounds 1a-g, 2, 3, 6a-d, 6f, 7a, 7b and 7d were evaluated for their activity toward three different Leishmania sp., while their cytotoxicity against two established mammalian cell lines was investigated.
| METHODS AND MATERIALS

| Chemistry
Melting points were determined using a Büchi capillary apparatus and are uncorrected.
1 H and 13 C NMR spectra were , and solvent gradient of A/B was 95/5 to 0/100. The analyses were performed at r.t. with a constant flow rate of 1 ml/min using a gradient elution of 0-50 min. The commercial reagents were purchased from Alfa Aesar, Sigma-Aldrich and Merck, and were used without further purification except for the benzyl bromoacetate. This reagent was purified by distillation in vacuo prior to use. O-(4-Methoxybenzyl)hydroxylamine was synthesized according to the literature reported method. [9] Organic solvents used were of the highest purity, and when necessary, were dried by the standard methods. Yields refer to chromatographically pure materials. Carboxylic acid 47 (1.33 g, 3.82 mmol) was treated with 1,1′-carbonyldiimidazol (743 mg, 4.58 mmol) in dry THF (75 ml) as described for the preparation of 58 from 45. [7] Then, O-benzyl hydroxylamine hydrochloride (731 mg, 4.58 mmol) and triethylamine (509 mg, 5.04 mmol) were added, and the mixture was stirred at 28°C for 25 hr under argon. The reaction was worked up following the same procedure described in 58, and the resulting viscous oil was chromatographed on silica gel column with AcOEt-n- Compound 60 (856 mg, 1.89 mmol) was subjected to catalytic hydrogenation (H 2 /Pd-C, 103 mg) in abs EtOH (90 ml) following the procedure previously described. [7] The hydrogenation product was chromatographed on silica gel column using AcOEt-n- 
| (S)-N-Hydroxy-6-[(2-methylthio) ethyl]-3,5-dioxospiro[piperazine-2,2′-tricyclo [3.3.1.1 3,7 ]decane]-4-acetamide 1e
A mixture of benzyl ester 34 (850 mg, 1.86 mmol) and 10% Pd on charcoal (1,275 mg) in EtOH-AcOEt 3:2 (70 ml) was hydrogenated as described for the preparation of 45 from 31 [10] to give a white foamy solid (646 mg Compound 61 (360 mg, 0.76 mmol) was subjected to catalytic hydrogenation (10% Pd-C, 550 mg) in EtOHAcOEt 3:2 (35 ml) following the procedure previously described. [7] The hydrogenation material was chromatographed over flash silica eluting first with AcOEt-n- 
| (RS)-6-[(4-Chlorophenyl)methyl]-N-
hydroxy-2,6-dioxospiro[piperazine-2,2′-tricyclo [3.3.1.1 3,7 ]decane]-4-acetamide 3
A mixture of 4-methoxybenzyl ester 38 (1.0 g, 1.86 mmol) and TFA (3 ml) in CH 2 Cl 2 (20 ml) was stirred for 90 min. The solution was evaporated to dryness under reduced pressure, and the residue was dissolved in dry THF (36 ml). Triethylamine (304 mg, 3 mmol) and 1,1′-carbonyldiimidazol (364 mg, 2.24 mmol) were added, and the mixture was stirred at 28°C for 1 hr under argon. After this time, O-(4-methoxybenzyl) hydroxylamine (344 mg, 2.24 mmol) was added, and the mixture was stirred 24 hr at 28°C and 1 hr at 55°C under argon. The reaction was then worked up in the same way described for the preparation of 58 from 45 [7] . The resulting thick oil was chromatographed on silica gel column with AcOEt-nhexane 1:2, as eluent, to afford the corresponding O-benzyl hydroxamate 65 as a white foamy solid, which strongly binds the elution solvents. Removal of the entrapped solvents as in 60 gave 65 as a glass solid (715 mg, 70%). This compound appears in the 1 H and 13 C NMR spectra as a mixture of E/Z .0 (100). A mixture of compound 65 (451 mg, 0.82 mmol) and TFA (6 ml) in CH 2 Cl 2 (23 ml) was stirred for 10 min. The solution was then treated dropwise with Et 3 SiH (600 μl) via syringe, and the stirring was continued for 45 min at room temperature. In this time window, the color changed from ruby to pale yellow. The reaction mixture was evaporated to dryness under reduced pressure, and the residual material was quenched with water (15 ml) and ether (50 ml) under vigorous stirring. To this stirred two phase mixture was added solid Na 2 CO 3 to pH = 8-9. The organic layer was separated and the water phase was extracted with ether (3 × 40 ml). The combined organics were washed with brine (50 ml), dried (Na 2 SO 4 ) and evaporated to dryness. The thick oily residue was chromatographed on silica gel column with AcOEt-n-hexane 2:1, as eluent, to afford the title compound 3 as a white foamy solid, which binds the elution solvents. Removal of the entrapped solvents as in 1d gave 3 as an off-white semi-foamy solid (313 mg, 89%): 1 
| (S)-N-Hydroxy-2-(2-methylpropyl)-
3,5-dioxo-1.4-diazaspiro[5.7]tridecane-4-acetamide 6d
Carboxylic acid 54 (1.13 g, 3.5 mmol) was treated with 1, 1′-carbonyldiimidazole (681 mg, 4.2 mmol) in dry THF-DMF 6:1 (70 ml) as described for the preparation of 58 from 45. [7] Then O-benzylhydroxylamine hydrochloride (670 mg, 4.2 mmol) and triethylamine (468 mg, 4.62 mmol) were added, and the mixture was stirred at 28°C for 25 hr under argon. The reaction was worked up in exactly the same way described in 58, and the resulting viscous oil was chromatographed on silica gel column with AcOEt-n- , 100), 91.0 (90). Compound 70 (1.19 g, 2.8 mmol) was subjected to catalytic hydrogenation (10% Pd-C, 143 mg), in abs EtOH (126 ml) following the procedure previously described. [7] The hydrogenation material was chromatographed on silica gel column eluting first with AcOEt-n-hexane 1:1 and then AcOEt to afford the title compound 6d as a white foamy solid, which strongly binds the eluting solvent. Removal of the entrapped solvent as in 1e gave 6d as an off-white solid (850 mg, 90.5%): mp 129-132°C; 1 
| (S)-N-Hydroxy-2-(2-methylpropyl)-3,5-dioxospiro-1,4-diazaspiro[5.6]dodecane-4-acetamide 7d
Carboxylic acid 57 (1.52 g, 4.9 mmol) was treated with 1,1′-carbonyldiimidazol (957 mg, 5.9 mmol) in dry THF-DMF 6:1 (100 ml) as described for the preparation of 58 from 45. [7] Then, O-benzylhydroxylamine hydrochloride (942 mg, 5.9 mmol) and triethylamine (657 mg, 6.5 mmol) were added, and the mixture was stirred at 28°C for 25 hr under argon. The reaction was worked up in exactly the same way described in 58, and the resulting thick oil was chromatographed on silica gel column with AcOEt-n- Compound 73 (1.62 g, 3.9 mmol) was subjected to catalytic hydrogenation (10% Pd-C, 194 mg), in abs EtOH (175 ml) following the procedure previously described. [7] | ZOIDIS et al.
The hydrogenation material was chromatographed on silica gel column with AcOEt-n-hexane 3:1, as eluent, to afford the title compound 7d as a white foamy solid, which strongly binds the aforementioned solvents. Removal of the entrapped solvent as in 1e gave 7d as an off-white crystalline solid (1.18 
| Biological evaluation
| Trypanocidal assays
Bloodstream form T. brucei (strain 221) were cultured in modified Iscove's medium, as outlined previously. [11] Assays were performed in 96-well microtiter plates and the compound concentrations which inhibited growth by 50% (IC 50 ) and 90% (IC 90 ) were determined. Parasites were first diluted to 2.5 × 10 4 ml −1 , compounds were added at range of concentrations, and the plates incubated at 37°C. Resazurin was added after 48 hr (12.5 μg/ml), the plates incubated for a further 16 hr, and then read in a Spectramax plate reader (excitation 555 nm/emission 585 nm). Results were analyzed using GraphPad Prism. Each drug concentration was tested in triplicate. Trypanosoma cruzi epimastogotes (strain CL Brener) were cultured as described. [12] Trypanocidal activity was determined in microtiter plates as outlined above, with the following modifications. Experiments were initiated by seeding the parasites at 2.5 × 10 5 ml −1 , and after the addition of test compounds, cultured at 28°C for 4 days. Resazurin was added, the plates were incubated for a further 2 days, and then assessed as above.
| Leishmanicidal assays and cytotoxicity assays on murine macrophages J774.1. cells
Leishmania donovani (strain LG13, MHOM/ET/0000/ HUSSEN), Leishmania infantum (MHOM/GR/2002/GH12) and L. amazonensis (MPRO/BR/72/M1845) promastigotes were cultured at 26°C in RPMI 1640 (RPMI) medium supplemented with 10% heat-inactivated fetal bovine serum (fully supplmented RPMI), 10 mm HEPES and antibiotics (penicillin/streptomycin) as previously described. [13] The murine macrophage J774.1 cell line (American Type Culture Collection, Manassas, VA) was cultured as well as described above, in fully supplemented RPMI, and incubated at 37°C in 5% CO 2 . The inhibitory activity and the cytotoxicity of the compounds were determined with the use of an MTT-based assay, the Alamar blue, as previously described. [14] More specifically, 2.5 × 10 6 parasites/ml and 2 × 10 5 macrophages/ml were seeded into 96-well plates (in total volume 200 μl) and they were incubated for 72 hr with different concentrations of the compounds at 26 and 37°C (in 5% CO 2 ) respectively. 20 μl of Alamar blue were added upon the 72-hr incubation and 24 hr later the colorimetric readings were performed (wavelength: 550 nm, reference wavelength: 620 nm). The 50% maximal inhibitory concentration (IC 50 ) was calculated using a nonlinear regression curve fit. [15] For evaluating the inhibitory activity of compounds against intracellular amastigotes, J774.1 macrophages were seeded into 96-well flat bottom plates at a density of 2 × 10 5 cells/ml and a total volume of 200 μl and were left to adhere overnight at 37°C in 5% CO 2 . Then, the macrophages were infected with stationary phase 4 × 10 6 promastigotes/ml, at a ratio of 10 parasites per 1 macrophage, and incubated for a further 24 hr at 37°C in 5% CO 2 as previously described. [14] Upon the incubation, the medium was removed, wells were thoroughly washed with PBS to remove free parasites, and 200 μl of fresh medium containing the different concentrations of the compounds was added. The plate was incubated for further 72 hr at 37°C in 5% CO 2 and 20 μl of Alamar blue was added as described above. All experiments were performed at least three independent times in triplicate.
| Cytotoxicity assays on rat skeletal myoblast L6 cells
Cytotoxicity against L6 cells was assessed using microtiter plates. Briefly, cells were seeded in triplicate at 1 × 10 4 ml −1
in growth medium containing different compound concentrations. The plates were incubated for 6 days at 37°C and resazurin then added to each well. After a further 8 hr incubation, the fluorescence was determined using a Spectramax plate reader.
| RESULTS AND DISCUSSION
| Chemistry
The synthetic routes for the preparation of the target compounds (1a-g, 2-5, 6a-d, 6f, 7a, 7b and 7d) are illustrated in Scheme 1. 2,6-Diketopiperazine-1-acetic acids 45-57 and 83-85 were the pivotal intermediates in preparing the acetohydroxamic acid analogues 1a-g, 2, 4, 5, 6a-d, 6f, 7a, 7b , and 7d. Thus, the coupling of these carboxylic acids with Obenzylhydroxylamine or O-benzyl-N-methylhydroxylamine in the presence of 1,1′-carbonyldiimidazol (CDI) in THF or THF-DMF mixtures afforded the corresponding O-benzyl hydroxamates 58-64, 66-73 and 86-88 in yields 58%-95%. Subsequent benzyl deprotection by hydrogenation over 10% Pd-C gave the respective hydroxamic acids 1a-g, 2, 4, 5, 6a-d, 6f, 7a, 7b, and 7d. It is of note that this reductive deprotection provided 1a-d, 1f, 1g, 2, 4, 5, 6a-d, 6f, 7a, 7b and 7d in high yields (80%-96%), while it was low-yielding (<10%) for 1e. This is presumably due to catalyst poisoning by the methionine sulfide group. A better yield of 1e (25%) was achieved when the catalyst amount was 1.5-fold the weight of its corresponding O-benzyl hydroxamate precursor 61.
The preparation of the chloro-substituted hydroxamic acid 3 needed an alternative synthetic process as shown in Scheme 1. 4-Methoxybenzyl ester 38 was treated with trifluoroacetic acid (TFA) to give the respective carboxylic acid (not shown), which was coupled with O-(4-methoxybenzyl)hydroxylamine in the presence of CDI to form the O-(4-methoxybenzyl) hydroxamate 65 (70% from 38). Removal of the 4-methoxybenzyl protecting group of 65 was effected by treatment with trifluoroacetic acid in the presence of triethylsilane to give the desired compound 3 in 89% yield. The requisite 4-methoxybenzyl ester 38 was synthesized from 24 as described for the preparation of the benzyl esters 31-37 and 39-44, except that 4-methoxybenzyl bromoacetate was used in place of benzyl bromoacetate. It is noteworthy that the 4-methoxybenzyl bromoacetate [16, 17] used was prepared by employing a new facile and efficient experimental protocol involving the treatment of 4-methoxybenzyl alcohol with bromoacetyl chloride in the presence of NaHCO 3 in dry CH 2 Cl 2 (Supporting Information). The 1 H and 13 C NMR spectra for all acetohydroxamic acid analogues (compounds 1a-g, 2-5, 6a-d, 6f, 7a, 7b, and 7d) are consistent with a Z/E conformational behavior of these molecules in solution. The NMR spectral data of compounds 1a-c, 1f, 1g, 2, 6a-c, 6f, 7a, and 7b have already been reported. [7] However, the assignment of the Z and E conformers given in this report was erroneous. Our next, more detailed conformational study, [8] has reversed these assignments; that is, the original data referring to the E-isomer correspond to the Z-isomer structure and vice versa.
| Biological evaluation
Compounds 1a-g, 2-5, 6a-d, 6f, 7a, 7b, and 7d were tested against bloodstream form T. brucei in vitro. Analogues 1a, 1b, and 1f were also tested against T. cruzi epimastigotes.
The results are shown in Table 1 Table 2 . The cytotoxicities of the hydroxamic acid derivatives against mammalian cells were determined using the rat skeletal myoblast L6 and murine macrophage J 174.1 cell lines. Inspection of Table 1 shows that compounds 1a-g, 2, 3, 6a-d, 6f, 7a, 7b and 7d exhibited potent activity against T. brucei as either free bases or hydrochloride salts (IC 50 = 6.6-1,870 nm and 9.2-1,150 nm respectively). In particular, compounds 1f, 1g, 2, 3, 6d and 6f were the most potent against African trypanosomes, with IC 50 values in the low nanomolar range (6.8-72 nm), while hydroxamates 1a, 1b and 1f were found to be significantly active against T. cruzi epimastigotes. Structure-activity relationship studies show that the substitution pattern of the spiro carbocyclic 2,6-DKP scaffold is an essential factor in the trypanocidal potency of these acetohydroxamic acid-based analogues.
Methylation on the basic nitrogen of the 2,6-DKP ring of the adamantane parent compound 1a resulted in 2.1-fold less activity against T. brucei (compare 1b versus 1a) . However, analogous methylation on the cyclooctane and cycloheptane parent molecules 6a and 7a provided a 1.9 and 6.6-fold increase in the potency of their N-methyl analogues 6b and 7b, respectively (Table 1) . These results indicate that N-methyl substitution on the 2,6-DKP ring has a favorable effect on the trypanocidal activity only in the cases of the cyclooctane or cycloheptane-containing acetohydroxamic acid analogues in this series of compounds.
We next investigated the effect of alkyl or arylmethyl substitution at the vicinal position of the basic nitrogen atom within the spiro carbocyclic 2,6-DKP framework, using methyl, isobutyl, 2-(methylthio)ethyl, benzyl and 4-chlorobenzyl substituents. As shown in Table 1 , introduction of a methyl, isobutyl or 2-(methylthio)ethyl substituent to the adamantane parent 1a, leading to the (S)-enantiomer of the corresponding C-alkylated analogues 1c, 1d and 1e, reduced potency against T. brucei. Compounds 1c, 1d, and 1e, in the free base form, were 1.5, 3.1 and 1.9-fold less potent than 1a. The lowest activity relative to 1a resulted from the introduction of an isobutyl group (1d). However, similar C-methylation or isobutylation of the cyclooctane parent molecule 6a appeared to have a beneficial effect on the trypanocidal potency; the resulting (S)-methyl and (S)-isobutylsubstituted analogues 6c and 6d had 2.4 and 4.2-fold better activities than 6a, respectively. It is interesting that a significantly improved activity (19-fold) was observed with the cycloheptane-containing (S)-isobutyl-substituted congener 7d relative to the parent compound 7a. Therefore, the presence of a methyl or isobutyl group at the vicinal position of the amine nitrogen atom in the 2,6-DKP ring seems to favor trypanocidal potency toward T. brucei in the context of the spiro cyclooctane or cycloheptane 2,6-diketopiperazine-1-acetohydroxamic acids.
Attachment of a bulky hydrophobic substituent, such as a benzyl or 4-chlorobenzyl group, to the methylene carbon in the 2,6-DKP ring of the parent molecules 1a and 6a led to the most potent analogues (1f, 1g, 2, 3 and 6f) in this series against bloodstream form T. brucei, with activity in low nanomolar range (IC 50 = 6.8-32 nm, Table 1 ). Of the adamantane-based compounds possessing a benzyl substituent, the S-enantiomer (1f, IC 50 = 6.8 nm) was more potent than the R-enantiomer counterpart (1g, IC 50 = 9.1 nm), or racemate (2, IC 50 = 17 nm). Their activities in the free base form were found to be 5.3-13 times higher than the unsubstituted parent 1a and 8-42 times higher than their C-methyl and C-isobutyl-substituted congeners 1c and 1d. Incorporation of a 4-chlorobenzyl substituent at the same position of the parent 1a, leading to the racemate p-chlorobenzylsubstituted derivative 3, caused an increase in activity (2.8-fold), albeit to a lesser extent than the respective benzylic substitution (racemate 2 versus 3). A similar potency profile was observed for the cyclooctane C-benzyl-substituted analogue 6f (S-enantiomer). This compound was significantly more potent (10-fold) than the parent 6a and had 4.3 and 2.5 more trypanocidal activity than the (S)-enantiomers of the C-methyl and C-isobutyl counterparts 6c and 6d, respectively ( Table 1 ). The higher increase in potency of the C-benzylated analogues 1f, 1g, 2, 3, and 6f is ascribed to the strongly favorable stereoelectronic and lipophilic effects exerted by the benzylic substituent in the binding site. of acetohydroxamic acid analogues 1a-g, 2-5, 6a-d, 6f, 7a, 7b and 7d (Figure 1 ) tested against cultured bloodstream form T. brucei (pH = 7.4) and T. cruzi epimastigotes, and cytotoxicity of the most active compounds against cultured rat skeletal myoblast L6 cells (Supporting information) The adamantane-containing free bases 1a, 1b, and 1f were significantly active against cultured T. cruzi epimastigotes, with micromolar to submicromolar IC 50 values (Table 1) . It is noteworthy, that N-methylation in analogue 1b leads to an opposite effect to that in T. brucei. Similarly, C-benzylation on 1a, giving compound 1f, led to a much more potency against T. cruzi (26-fold). [7] The results of the in vitro assay for the antileishmanial activity of compounds 1a-g, 2, 3, 6a-d, 6f, 7a, 7b , and 7d are presented in Table 2 . These compounds were first screened against the promastigote form of each of the three Leishmania sp. at 10 μm. IC 50 values were further determined for those displaying 100% parasite growth inhibition at this concentration.
T A B L E 1 Activity
The unsubstituted parent compounds 1a, 6a, 7a and their substituted derivatives 1b, 1c, 1e, 6b, 6c, 6f, and 7b had a marginal activity toward all the Leishmania sp. tested. In contrast, compounds bearing an isobutyl substituent at the vicinal position of the nitrogen atom of the respective spiro carbocyclic 2,6-DPK residue (1d, 6d, 7d) , or compounds possessing a benzylic or 4-chlorobenzylic substituent at the same position of the adamantane-based spiro 2,6-DPK core (1f, 1g, 2, 3) , exhibited significant activities against L. infantum promastigotes and intracellular amastigotes, in either free base form or hydrochloride salt, with IC 50 values at micromolar to low micromolar levels. Their antipromastigote and antiamastigote activities in the free base form were in the range of 2.67-17.7
